

TRICARE Prior Authorization Request Form for
teriparatide 600 mcg (Forteo and generic)



JOHNS HOPKINS
 HEALTH PLANS

7231 Parkway Drive, Suite 100, Hanover, MD 21076

**FAX Completed Form and
 Applicable Progress Notes to:
 (410) 424-4037**

USFHP Pharmacy Prior Authorization Form

| To be completed by Requesting provider | |
|--|----------------------|
| Drug Name: | Strength: |
| Dosage/Frequency (SIG): | Duration of Therapy: |

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Prior authorization expires after 24 months

Step 1 Please complete patient and physician information (please print):

| | |
|----------------------|-----------------------|
| Patient Name: _____ | Physician Name: _____ |
| Address: _____ | Address: _____ |
| Sponsor ID #: _____ | Phone #: _____ |
| Date of Birth: _____ | Secure Fax #: _____ |

Step 2 Please complete the clinical assessment:

| | | |
|--|---|---|
| 1. The brand Forteo formulation is the preferred product over generic teriparatide and is covered at the lowest copayment, which is the generic formulary copayment for non-Active-Duty patients, and at no cost share for Active-Duty patients. (Although Forteo is a branded product, it will be covered at the generic formulary copayment or cost share) Please type "Acknowledge" and proceed to the next question. | Proceed to question 2 | |
| 2. Is the patient GREATER THAN or EQUAL to 18 years of age? | <input type="checkbox"/> Yes Proceed to question 3 | <input type="checkbox"/> No STOP Coverage not approved |
| 3. Is Forteo being prescribed for treatment of osteoporosis, and not for prevention of osteoporosis? | <input type="checkbox"/> Yes Proceed to question 4 | <input type="checkbox"/> No STOP Coverage not approved |
| 4. Is the patient a postmenopausal female with osteoporosis? | <input type="checkbox"/> Yes Proceed to question 7 | <input type="checkbox"/> No Proceed to question 5 |
| 5. Is the patient male with primary or hypogonadal osteoporosis? | <input type="checkbox"/> Yes Proceed to question 7 | <input type="checkbox"/> No Proceed to question 6 |
| 6. Does the patient have osteoporosis associated with sustained systemic glucocorticoid therapy (for example, GREATER THAN 6 months use of GREATER THAN 7.5mg/day prednisone or equivalent)? | <input type="checkbox"/> Yes Proceed to question 7 | <input type="checkbox"/> No STOP Coverage not approved |

TRICARE Prior Authorization Request Form for teriparatide 600 mcg (Forteo and generic)

| | | |
|---|---|--|
| 7. Is the patient at high risk for fracture defined as one of the following; history of osteoporotic fracture, multiple risk factors for fracture (for example, a history of vertebral fracture or low-trauma fragility fracture of the hip, spine or pelvis, distal forearm or proximal humerus)? | <input type="checkbox"/> Yes Proceed to question 10 | <input type="checkbox"/> No Proceed to question 8 |
| 8. Does the patient have a bone mineral density (BMD) T-score of -2.5 or worse? | <input type="checkbox"/> Yes Proceed to question 10 | <input type="checkbox"/> No Proceed to question 9 |
| 9. Has the patient tried and experienced an inadequate response to, therapeutic failure with, is intolerant to (unable to use or absorb), or has contraindications to at least one formulary osteoporosis therapy (for example, alendronate, ibandronate)? | <input type="checkbox"/> Yes Proceed to question 10 | <input type="checkbox"/> No STOP Coverage not approved |
| 10. Will the patient continue to take calcium and vitamin D supplementation during PTH analog therapy if dietary intake is inadequate? | <input type="checkbox"/> Yes Proceed to question 11 | <input type="checkbox"/> No STOP Coverage not approved |
| 11. Will the cumulative treatment with Forteo and Tymlos exceed 24 months during the patient's lifetime? | <input type="checkbox"/> Yes STOP Coverage not approved | <input type="checkbox"/> No Proceed to question 12 |
| 12. What is the requested medication? | <input type="checkbox"/> brand Forteo Sign and date below | <input type="checkbox"/> generic teriparatide Proceed to question 13 |
| 13. Please provide a patient-specific justification as to why the brand Forteo cannot be used in this patient. | <hr style="border: 0; border-top: 1px solid black; margin-bottom: 10px;"/> Sign and date below | |

Step 3 I certify the above is true to the best of my knowledge. Please sign and date:

Prescriber Signature

Date

[27 Dec 2023]

| For Internal Use Only | |
|--|-------------------------------------|
| <input type="checkbox"/> Approved: | Duration of Approval: ____ month(s) |
| <input type="checkbox"/> Denied: | Authorized By: |
| <input type="checkbox"/> Incomplete/Other: | PA#: |
| Date Faxed to MD: | Date Decision Rendered: |